Method of treatment of myocardial infarction

Abstract

Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.

1 . A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor. 
     
     
         2 . The method of  claim 1  wherein the mammal is a human. 
     
     
         3 . The method of  claim 1  wherein the mammal is a non-human mammal. 
     
     
         4 . The method of  claim 1  wherein the Src family tyrosine kinase inhibitor is a an inhibitor of Src protein. 
     
     
         5 . The method of  claim 4  wherein the chemical inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. 
     
     
         6 . The method of  claim 5  wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is a member of the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, and a mixture thereof. 
     
     
         7 . The method of  claim 5  wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is a member of the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof. 
     
     
         8 . The method of  claim 5  wherein the pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor is PD173955. 
     
     
         9 . The method of  claim 5  wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606. 
     
     
         10 . The method of  claim 1  wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection. 
     
     
         11 . The method of  claim 1  wherein the pharmaceutical composition is administered to the mammal by intravenous injection. 
     
     
         12 . The method of  claim 1  wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction. 
     
     
         13 . The method of  claim 1  wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction. 
     
     
         14 . A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor. 
     
     
         15 . The method of  claim 14  wherein the mammal is a non-human mammal. 
     
     
         16 . The method of  claim 14  wherein the mammal is a human. 
     
     
         17 . The method of  claim 14  wherein the pharmaceutical composition is orally administered to the mammal. 
     
     
         18 . The method of  claim 14  wherein the pharmaceutical composition is parenterally administered to the mammal. 
     
     
         19 . The method of  claim 15  wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine class Src family tyrosine kinase inhibitor. 
     
     
         20 . The method of  claim 19  wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, and a mixture thereof. 
     
     
         21 . The method of  claim 14  wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile compound. 
     
     
         22 . The method of  claim 5  wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is 4-amino-5-(4-methylphenyl)-7-(t-butyl)-pyrazolo[3,4-d-]pyrimidine. 
     
     
         23 . The method of  claim 19  wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is 4-amino-5-(4-methylphenyl)-7-(t-butyl)-pyrazolo[3,4-d-]pyrimidine.